転移しない小細胞膀がんの治療方法:再構築されたカプラン・マイヤー曲線のメタ解析

Lucas Mose¹, Priyamvada Maitre², Pascal Eberz¹

¹Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland.

Clinical and translational radiation oncology

|September 2, 2025

まとめ

このメタ解析では,化学療法と急性半球切除術または放射線治療が,小細胞膀がん (SCBC) 患者における全生存率を改善することを発見した. 局所治療だけで,比較可能な生存結果を示した.

科学分野:

泌尿腫瘍学
医療腫瘍学
癌研究

背景:

小細胞膀癌 (SCBC) は,最適な治療戦略が不確実な攻撃的な癌です.
現在の選択肢は根絶性半球切除術,化学療法,放射線療法で併用されることが多い.

研究の目的:

非転移性SCBCの治療方法に関する現在の文献を評価する.
SCBCの異なる治療法の有効性を分析し比較する.

主な方法:

2024年3月まで4つの主要なデータベース (PubMed,Scopus,Web of Science,Cochrane Library) で包括的な文献検索が行われました.
非転移性SCBCの治療アプローチを比較した12件の適格な研究をメタ分析した.

主要な成果:

ラジカル・システクトミーによる治療と放射線療法による治療の間で,全生存率 (OS) の有意な差は認められなかった (HR=1. 04, p=0. 6).
放射線治療と化学療法を併用すると,OSの有意な改善が見られた (HR=0. 53,p< 0. 0001).
局所療法のみ (19. 67ヶ月) または化学療法のみ (19. 20ヶ月) と比較して,化学療法による平均生存率は高かった.

結論:

ラジカル・システクトミーと放射線療法は,非転移性SCBCでは比較可能な生存結果を示しています.
化学療法と局所療法 (組織切除または放射線療法) を併用すると,全生存率が向上するようです.
研究の高度な異質性は,これらの発見を慎重に解釈する必要がある.

キーワード:

化学療法全体の生存率ラジカル・システクトミー放射線療法小細胞膀がん

さらに関連する動画

11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K

08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.8K

関連する概念動画

01:24

Kaplan-Meier Approach

258

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

258

01:21

Cancer Survival Analysis

448

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

448

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

02:50

Combination Therapies and Personalized Medicine

5.1K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...